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CASE REPORT
Serum fluoxetine and norfluoxetine 
levels support the safety of fluoxetine 
in overdose
Stephanie Pope*  and Solomon G. Zaraa
Abstract 
Background: Previous literature has found fluoxetine to be relatively safe in overdose. This study hopes to examine 
this idea along with support from published pharmacokinetic information including serum fluoxetine and norfluox-
etine levels based on information from a clinical case series.
Methods: Four cases are presented along with vital abnormalities, electrocardiogram abnormalities, and physical 
exam abnormalities along with amount of overdose and resulting serum fluoxetine and norfluoxetine levels.
Case Presentation: In these four cases, serum fluoxetine and norfluoxetine days after overdose were found to be 
in a range believed to be within the treatment range. No abnormalities were found on electrocardiogram but some 
patients (3) were found to have slight elevations in heart rate.
Conclusion: Fluoxetine is relatively safe in overdose. This study supports previous literature. Future directives 
for research can be directed towards when serotonergic, including fluoxetine, medications can be introduced or 
restarted in patients who have overdosed. Research could also focus on if the introduction of another medication, 
such as carbamazepine, to induce metabolism of a medication, such as fluoxetine, after an overdose.
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Previous research has provided ample evidence to con-
clude fluoxetine without tricyclic antidepressants as 
relatively safe in overdose. Early literature found sinus 
tachycardia, convulsions, depressed ST segments on 
electrocardiogram (ECG), elevated diastolic blood pres-
sure, drowsiness, and agitation in a series of case reports 
and chart reviews of fluoxetine in overdose [1–5]. A 
larger chart review of 234 cases was completed including 
20 pediatrics patients and 67 patients who ingested fluox-
etine alone. In this chart review, the 20 pediatric patients 
ranged in age between 10  months and 4  years old. The 
mean dose ingested was 23.4  mg or 1.76  mg/kg. Of the 
20 pediatric patients, 18 remained asymptomatic, while 
hyperactivity and diarrhea were reported in a 2-year-old 
and sleepiness was reported in a 23-month old. Of the 67 
adults in this study, the mean dose ingested was 544 mg, 
while 30 were asymptomatic, 15 were found to have tach-
ycardia, 14 reported drowsiness, five with tremor, four 
with vomiting and four with nausea, one with eupho-
ria, one with headache, one with sore throat, one with 
trigeminy, one with junctional rhythm, and one with 
abdominal pain [6].
Meanwhile, serum concentrations of fluoxetine and 
its active demethylated metabolite, norfluoxetine, have 
been studied. One study found four patients were treated 
with 80  mg/day for 52 ±  8  weeks and had their serum 
measured for fluoxetine and norfluoxetine while taking 
the medication and then 4 and 8 weeks after discontin-
uation. Mean fluoxetine and norfluoxetine levels dur-
ing treatment were 620  ±  49  ng/ml and 496  ±  49  ng/
ml, respectively. After 4 weeks of discontinuation, mean 
fluoxetine and norfluoxetine levels during treatment were 
55 ±  19  ng/ml and 184 ±  40  ng/ml, respectively. After 
8 weeks of discontinuation, fluoxetine and norfluoxetine 
levels during treatment were 0 ng/ml and 47 ± 20 ng/ml, 
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respectively. Age and sex of the patient did not impact 
metabolism of this study [7]. Two other studies found sex 
did impact serum concentrations and metabolisms. In a 
study of 10–17 year olds [8] and adults [9], it was found 
that males had lower fluoxetine and norfluoxetine serum 
levels similar to comparing Case 1 and Case 2 although 
admitting vastly less sophisticated.
Unfortunately, Patients have continued to overdose 
with fluoxetine. The purpose of this study is to examine 
serum fluoxetine and norfluoxetine levels as a product 
of time from fluoxetine overdose in relationship to their 
clinical presentations. The goal of this study is to address 
the gap of knowledge and complications from fluoxetine 
overdose in clinical cases. The hypothesis of this study is 
that fluoxetine is relatively safe in overdose.
Methods
Participants were identified by the authors as minors 
admitted to an acute psychiatric unit for fluoxetine over-
dose between January 1, 2011 and April 1, 2015. Pregnant 
patients were excluded. Once patients were identified, 
their charts were reviewed and data such as age, sex, 
vitals, serum fluoxetine and norfluoxetine levels, electro-
cardiograms and physical exam findings, and psychiatric 
medication administered during hospitalization after the 
reported intentional overdose were extracted from the 
chart. This information was then correlated to existing 
literature, specifically plasma concentrations of fluox-
etine and norfluoxetine.




17-year-old female admitted for an intentional overdose 
of 120  mg of Fluoxetine. She was found two days after 
her ingestion to be diffusely hyper-reflexic and this was 
thought to be due to an elevation in serotonin. She was 
restarted on her outpatient regimen of fluoxetine 30 mg 
5  days after her ingestion. After approximately 144  h 
from her ingestion and one administration of her out-
patient dose the day prior, her serum fluoxetine level 
was 139  ng/mL and her serum norfluoxetine level was 
205 ng/mL.
Case 2
16-year-old male admitted for an intentional overdose 
of 680  mg of Fluoxetine with 10 unknown dose tablets 
of acetaminophen. After approximately 148  h from his 
ingestion, his serum fluoxetine level was 226 ng/mL and 
his serum norfluoxetine level was 205 ng/mL. He was ini-
tially admitted to the intensive care unit and monitored 
for transaminitis which he ultimately did not suffer from. 
He was transferred to the acute inpatient psychiatric 
unit. Considering these levels, carbamazepine was dis-
continued and he was started on escitalopram targeting 
depression.
Case 3
14-year-old female admitted for an intentional overdose 
of an unknown amount of fluoxetine with phenylephrine, 
multivitamins, dextromethorphan, glucosamine, chlor-
pheniramine, and acetaminophen. She was obtunded 
on admission, given charcoal to induce vomiting and 
ultimately intubated. She was febrile and found to have 
aspiration pneumonia. Approximately 163  h after her 
ingestion, her serum fluoxetine level was 464 ng/mL and 
her serum norfluoxetine level was 453  ng/mL. Another 
blood draw 211 h after ingestion found her serum fluox-
etine level to be 163 ng/mL and her serum norfluoxetine 
level to be 468 ng/mL. Once she was medically well, she 
was transferred in an acute psychiatric unit. After her 
second serum fluoxetine draw, she was restarted on half 
of her outpatient dose of 40  mg PO daily for a day and 
then increased the next day to her outpatient dose of 
80 mg daily.
Case 4
15-year-old female admitted after an intentional over-
dose of 200  mg of fluoxetine with 30  mg of melatonin. 
Her serum fluoxetine was found to be 272  ng/mL and 
norfluoxetine to be 80 ng/mL about 67 h after ingestion. 
She was started on escitalopram 20  mg daily, the day 
after her serum blood drawn.
Results
Results are listed in Tables 1 and 2. 
Discussion
In all four of these cases, the levels found after an inten-
tional overdose (between 67 and 163 h later) were within 
levels considered therapeutic. Limitations in this study 
include the subjective matter of reporting an intentional 
overdose, amount and nature of the overdose and time 
of reports ingestion, and potential errors in document-
ing such information. Another limitation in this study 
includes the exclusion of CYP450 information. Future 
directives could include clinical correlations of safety 
compared to serum levels and CYP450 activities.
Vital abnormalities found included a heart rate slightly 
over 100. None of the patients had ECG abnormalities or 
elevations in diastolic blood pressure as noted by previ-
ous studies. One patient was febrile but this was most 
likely related to aspiration pneumonia. The majority 
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(three out of four) of these cases involved an ingestion of 
fluoxetine and other agents, which may complicate the 
pharmacokinetics and serum levels studied here.
The pharmacokinetics of fluoxetine and norfluoxetine 
is dependent on its administration either as an acute 
overdose or chronic therapy requiring weeks to reach 
stead state [7, 10–12]. This is beyond the scope of this 
study as administration prior to overdose was not col-
lected in the chart review.
Interestingly enough, Case 3, admittedly the most 
medical complicated in this series, was noted to have an 
increase in her serum norfluoxetine levels between the 
first and second blood draw. This could be related to a 
phenomenon found in a case of massive quetiapine over-
dose in which serum concentration levels did not follow 
first-order kinetics. This published case suggests that the 
initial concentration was related to quetiapine being dis-
tributed within tissues and slower redistribution from 
tissues to serum prior to hepatic metabolisms [13].
Conclusions
This study supports previous literature stating that fluox-
etine is relatively safe in overdose. Vitals, ECGs, and 
serum fluoxetine and norfluoxetine levels can be moni-
tored. Further research can be directed toward when 
serotonergic, including fluoxetine, medications can be 
introduced or restarted in patients who have overdosed.
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Table 1 CASES including demographic information, serum levels, and time after ingestion serum were drawn
F serum fluoxetine; NorF serum norfluoxetine
a Fluoxetine overdose with other medications in overdose
Age/sex BMI Overdose 
(mg)
1st level of F 
(ng/mL)















17F 28.4 240 139 205 144 Not completed Not completed Not completed
16M 21.1 680a 226 255 148 37 165 316
14F 20.0 Unknowna 464 453 163 338 468 211
15F 21.6 20a 272 80 67 Not completed Not completed Not completed
Table 2 CASES including ECG, vital and physical exam abnormalities
HR > 100 considered abnormal
Diastolic blood pressure > 100 considered abnormal
HR heart rate; HD hospital day; Ab abnormalities; ECG electrocardiogram; PE ab Physical exam abnormalities
Age/sex ECG ab Vital ab PE ab
17F None HR = 103 on HD #4 Hyperreflexia on the second day of hospitalization
16M None HR = 105 on presentation None
14F None Febrile due to pneumonia Obtunded on presentation
15F None HR = 102 on presentation None
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